SAbDab: The Structural Antibody Database

Search results

651 therapeutic(s) match your criteria. Click on the therapeutic name to open a summary page.
[NFD = No Further Development, (w) = Withdrawn, Semicolons delimit separate variable domains for bispecifics]
Click a column heading to sort by that attribute (may take a couple of seconds if the table contains many entries)

Therapeutic	Format	Highest Clinical Trial (Apr '21)	Est. Status (Apr '21)	Target	Year Proposed	100% SI Struc.	99% SI Struc.	95-98% SI Struc.
abagovomab	Whole mAb	Phase-III	Discontinued	CA125	2006	no	no	no
abelacimab	Whole mAb	Phase-II	Unknown	F11	2018	no	no	YES
abituzumab	Whole mAb	Phase-II	Active	ITGAV	2013	no	no	no
abrezekimab	Fab	Phase-I	Discontinued	IL13	2017	no	no	no
abrilumab	Whole mAb	Phase-II	Discontinued	α4β7	2014	no	no	no
acapatamab	Bispecific scFv	Phase-I	Active	FOLH1;CD3E	2020	no;no	no;no	no;no
acasunlimab	Bispecific mAb	Phase-I/II	Active	CD274;TNFRSF9	2020	no;no	no;no	no;no
actoxumab	Whole mAb	Phase-III	Discontinued	Toxin A	2012	no	no	no
adalimumab	Whole mAb	Approved	Active	TNFA	1999	YES	YES	no
adebrelimab	Whole mAb	Phase-III	Active	PDL1	2019	no	no	no
aducanumab	Whole mAb	Preregistration	Active	APP	2013	YES	no	no
afasevikumab	Whole mAb	Phase-I	Discontinued	IL17A	2015	YES	no	no
afutuzumab	Whole mAb	Approved	Active	MS4A1	2008	YES	YES	YES
alacizumab	di-Fab	Phase-II	Discontinued	KDR	2007	no	no	no
alemtuzumab	Whole mAb	Approved	Active	CD52	2000	YES	no	no
alirocumab	Whole mAb	Approved	Active	PCSK9	2012	no	no	no
alnuctamab	Bispecific mAb with Domain Crossover	Phase-I	Active	TNFRSF17;CD3E	2020	no;no	no;no	no;no
alomfilimab	Whole mAb	Phase-I/II	Active	ICOS	2020	YES	no	no
alsevalimab	Whole mAb	Phase-I	Active	VTCN1	2019	no	no	no
amatuximab	Whole mAb	Phase-II	Active	MSLN	2010	no	YES	no
amivantamab	Bispecific mAb	Preregistration	Active	EGFR;MET	2019	no;YES	no;no	no;no
amlitelimab	Whole mAb	Phase-II	Active	TNFSF4	2020	no	no	no
anbenitamab	Bispecific mAb	Phase-II	Active	ERBB2 (Domain II);ERBB2 (Domain IV)	2020	no;YES	no;YES	no;YES
andecaliximab	Whole mAb	Phase-III	Discontinued	MMP9	2016	YES	no	no
anetumab	Whole mAb ADC	Phase-II	Active	MSLN	2013	no	no	no
anifrolumab	Whole mAb	Preregistration	Active	IFNAR1	2013	YES	no	no
anrukinzumab	Whole mAb	Phase-II	Discontinued	IL13	2007	no	no	no
ansuvimab	Whole mAb	Approved	Active	Zaire Ebolavirus GP1	2020	no	YES	no
apamistamab	Whole mAb Radiolabelled	Phase-III	Active	PTPRC	2018	no	no	no
apitegromab	Whole mAb	Phase-II	Active	pro-GDF-8	2020	no	no	YES
aprutumab	Whole mAb ADC	Phase-I	Discontinued	FGFR2	2016	no	no	no
ascrinvacumab	Whole mAb	Phase-II	Active	ACVRL1	2015	no	no	no
astegolimab	Whole mAb	Phase-II	Active	IL1RL1	2019	no	no	no
atezolizumab	Whole mAb	Approved	Active	CD274	2014	YES	YES	no
atibuclimab	Whole mAb	Phase-II	Active	CD14	2020	no	no	no
atidortoxumab	Whole mAb	Phase-II	Discontinued	Toxin A	2017	no	no	no
atinumab	Whole mAb	Phase-I	Discontinued	RTN4	2010	no	no	no
atoltivimab	Whole mAb	Phase-I	Discontinued	Zaire Ebolavirus GP	2018	no	no	no
avdoralimab	Whole mAb	Phase-II	Active	C5AR1	2019	no	no	no
avelumab	Whole mAb	Approved	Active	CD274	2015	YES	no	no
avizakimab	Whole mAb	Phase-I/II	Active	IL21	2019	no	no	no
axatilimab	Whole mAb	Phase-II	Active	CSF1R	2019	no	no	no
azintuxizumab	Whole mAb ADC	Phase-I	Discontinued	SLAMF7	2016	no	no	no
balstilimab	Whole mAb	Preregistration	Active	PDCD1	2018	no	no	no
bamlanivimab	Whole mAb	Approved	Active	SARS-CoV-2 Spike	2020	YES	no	no
bapineuzumab	Whole mAb	Phase-II	Discontinued	APP	2005	no	no	YES
bapotulimab	Whole mAb	Phase-I	Active	ILDR2	2020	no	no	no
barecetamab	Whole mAb	Phase-I	Active	ERBB3	2020	YES	no	no
basiliximab	Whole mAb	Approved	NFD	IL2RA	1996	YES	no	no
batoclimab	Whole mAb	Phase-II/III	Active	FCGRT	2019	no	no	no
bavituximab	Whole mAb	Phase-III	Active	Phosphatidylserine	2006	no	no	no
bedinvetmab	Canine Whole mAb	Approved	Active	Canine NGFB	2018	no	no	no
befovacimab	Whole mAb	Phase-II	Active	TFPI	2019	no	no	no
begelomab	Whole mAb	Phase-II/III	Active	DPP4	2014	no	no	no
belantamab	Whole mAb ADC	Approved	Active	TNFRSF17	2017	no	no	no
belimumab	Whole mAb	Approved	Active	TNFSF13B	2003	YES	no	YES
bemarituzumab	Whole mAb	Phase-III	Active	FGFR2	2017	no	no	no
benralizumab	Whole mAb	Approved	Active	IL5RA	2009	no	no	no
bentracimab	Whole mAb	Phase-III	Active	AR-C124910XX	2020	YES	no	YES
benufutamab	Whole mAb	Phase-I/II	Active	TNFRSF10B	2019	YES	no	no
bepranemab	Whole mAb	Phase-I	Active	MAPT	2019	no	no	no
berlimatoxumab	Whole mAb	Phase-II	Discontinued	Toxin A	2017	YES	no	no
bermekimab	Whole mAb	Preregistration	Active	IL1A	2018	no	no	no
bersanlimab	Whole mAb	Phase-II	Discontinued	ICAM1	2017	no	no	no
bevacizumab	Whole mAb	Approved	Active	VEGFA	2000	YES	no	YES
bexmarilimab	Whole mAb	Phase-I/II	Active	STAB1	2019	no	no	no
bezlotoxumab	Whole mAb	Approved	NFD	Toxin A	2012	YES	no	no
bifikafusp	Whole mAb Fusion	Phase-III	Active	FN extra domain B	2010	no	no	no
bimagrumab	Whole mAb	Phase-II	Active	ACVR2B	2012	YES	YES	no
bimekizumab	Whole mAb	Preregistration	Active	IL17A	2013	no	no	no
bintrafusp	Whole mAb Fusion	Approved	Active	CD274	2015	YES	no	no
birtamimab	Whole mAb	Phase-III	Discontinued	SAA1	2018	no	no	no
bleselumab	Whole mAb	Phase-II	Active	CD40	2015	no	no	no
blinatumomab	Bispecific T-Cell Engager	Approved	Active	CD19;CD3E	2008	no;no	no;no	no;no
blontuvetmab	Canine Whole mAb	Unknown	Active	MS4A1	2015	no	no	no
blosozumab	Whole mAb	Phase-II	Active	SOST	2011	no	no	no
bococizumab	Whole mAb	Phase-III	Discontinued	PCSK9	2013	YES	no	no
botensilimab	Whole mAb	Phase-I	Active	CTLA4	2020	no	no	no
brazikumab	Whole mAb	Phase-III	Active	IL23A	2016	no	no	no
brentuximab	Whole mAb ADC	Approved	Active	TNFRSF8	2010	no	no	no
briakinumab	Whole mAb	Preregistration (w)	Discontinued	IL12B	2009	YES	no	no
brodalumab	Whole mAb	Approved	Active	IL17RA	2011	no	no	no
brolucizumab	scFv	Approved	Active	VEGFA	2014	no	no	no
brontictuzumab	Whole mAb	Phase-I	Discontinued	NOTCH1	2014	no	no	no
budigalimab	Whole mAb	Phase-I	Active	PDCD1	2018	no	no	no
burosumab	Whole mAb	Approved	Active	FGF23	2016	no	no	no
cabiralizumab	Whole mAb	Phase-II	Active	CSF1R	2015	no	no	no
cadonilimab	Bispecific Mixed mAb and scFv	Phase-II	Active	PDCD1;CTLA4	2020	no;no	no;no	no;no
camidanlumab	Whole mAb ADC	Phase-II	Active	IL2RA	2017	no	no	no
camrelizumab	Whole mAb	Approved	Active	PDCD1	2016	no	no	no
canakinumab	Whole mAb	Approved	Active	IL1B	2007	no	YES	no
cantuzumab	Whole mAb ADC	Phase-II	Discontinued	MUC1	2003	no	no	no
caplacizumab	Nanobody	Approved	NFD	VWF	2011	no	no	no
carlumab	Whole mAb	Phase-II	Discontinued	CCL2	2010	no	YES	no
carotuximab	Whole mAb	Phase-II	Discontinued	ENG	2015	no	no	no
casirivimab	Whole mAb	Approved	NFD	SARS-CoV-2 Spike RBD	2020	YES	no	no
cemiplimab	Whole mAb	Approved	Active	PDCD1	2018	no	no	no
cendakimab	Whole mAb	Phase-II	Active	IL13	2018	no	no	no
cergutuzumab	Whole mAb Fusion	Phase-I	Discontinued	CEACAM5	2015	no	no	no
certolizumab	Fab	Approved	Active	TNFA	2004	YES	no	no
cetrelimab	Whole mAb	Phase-II/III	Active	PDCD1	2017	no	no	no
cetuximab	Whole mAb	Approved	Active	EGFR	1999	YES	YES	YES
cevostamab	Bispecific mAb	Phase-I	Active	FCRL5;CD3	2019	no;no	no;no	no;no
cibisatamab	Bispecific mAb with Domain Crossover	Phase-I/II	Active	CEACAM5&CD3E;CD3E	2017	no;no	no;no	no;no
cilgavimab	Whole mAb	Phase-III	Active	SARS-CoV-2 Spike RBD	2020	no	no	no
cinpanemab	Whole mAb	Phase-II	Active	SNCA	2018	YES	no	no
citatuzumab	Fab Fusion	Phase-I	Discontinued	EPCAM	2008	no	no	no
cixutumumab	Whole mAb	Phase-II	Discontinued	IGF1R	2008	no	no	no
claudiximab	Whole mAb	Phase-III	Active	CLDN18	2017	no	no	no
clazakizumab	Whole mAb	Phase-III	Active	IL6	2012	no	no	no
clervonafusp	di-Fab Fusion	Phase-I/II	Active	SLC29A2	2018	no	no	no
clivatuzumab	Whole mAb Radiolabelled	Phase-III	Discontinued	MUC1	2009	no	no	no
cobolimab	Whole mAb	Phase-II/III	Active	HAVCR2	2018	no	no	no
codrituzumab	Whole mAb	Phase-II	Active	GPC3	2013	no	no	no
cofetuzumab	Whole mAb ADC	Phase-I	Active	PTK7	2017	no	no	no
coltuximab	Whole mAb ADC	Phase-II	Active	CD19	2013	YES	no	no
conatumumab	Whole mAb	Phase-II	Active	TNFRSF10B	2008	no	no	no
concizumab	Whole mAb	Phase-III	Active	TFPI	2012	YES	no	no
coprelotamab	Whole mAb	Phase-III	Active	ERBB2	2020	YES	YES	YES
cosfroviximab	Whole mAb	Phase-II	Active	Zaire Ebolavirus GP	2016	no	YES	no
cosibelimab	Whole mAb	Phase-I	Active	PDL1	2019	no	no	no
crenezumab	Whole mAb	Phase-III	Active	APP	2011	YES	YES	no
crizanlizumab	Whole mAb	Approved	Active	SELP	2016	no	no	no
crotedumab	Whole mAb	Phase-I	Discontinued	GCGR	2015	no	no	no
crovalimab	Whole mAb	Phase-III	Active	C5	2018	YES	no	no
cudarolimab	Whole mAb	Phase-I	Active	TNFRSF4	2019	no	no	no
cusatuzumab	Whole mAb	Phase-II	Active	CD70	2017	no	no	no
dacetuzumab	Whole mAb	Phase-II	Discontinued	CD40	2007	no	no	no
daclizumab	Whole mAb	Approved	Active	IL2RA	1994	YES	no	no
dafsolimab	Whole mAb	Phase-III	Active	CD3E	2020	no	no	no
dalotuzumab	Whole mAb	Phase-II	Active	IGF1R	2009	no	no	no
dapirolizumab	Fab	Phase-III	Active	CD40LG	2013	no	no	no
daratumumab	Whole mAb	Approved	Active	CD38	2009	no	no	no
datopotamab	Whole mAb	Phase-III	Active	TACSTD2	2019	no	no	no
daxdilimab	Whole mAb	Phase-I	Active	LILRA4	2020	no	no	no
dectrekumab	Whole mAb	Phase-II	Discontinued	IL13	2014	no	no	no
demcizumab	Whole mAb	Phase-I	Discontinued	DLL4	2012	no	no	no
demupitamab	Whole mAb	Phase-I	Active	EGFR	2019	no	YES	no
denintuzumab	Whole mAb ADC	Phase-II	Discontinued	CD19	2014	no	no	no
denosumab	Whole mAb	Approved	Active	TNFSF11	2005	no	no	no
depatuxizumab	Whole mAb ADC	Phase-III	Discontinued	EGFR	2016	no	no	no
depemokimab	Whole mAb	Phase-III	Active	IL5	2020	no	no	no
derlotuximab	Whole mAb Radiolabelled	Approved	Active	DNA/H1 Complex	2015	no	no	no
dezamizumab	Whole mAb	Phase-II	Discontinued	APCS	2016	no	no	no
dilpacimab	Bispecific mAb	Phase-II	Active	DLL4;VEGFA	2018	no;YES	no;no	no;YES
dinutuximab	Whole mAb	Approved	Active	Ganglioside GD2	2013	no	no	YES
diridavumab	Whole mAb	Phase-II	Active	Influenza A HA2	2014	YES	no	YES
disitamab	Whole mAb ADC	Phase-III	Active	ERBB2	2018	no	no	no
divozilimab	Whole mAb	Phase-II	Active	MS4A1	2020	no	no	no
docaravimab	Whole mAb (Mouse)	Approved	Active	Rabies Virus Strain ERA GP Ectodomain Epitope G-III	2019	no	no	no
domagrozumab	Whole mAb	Phase-II	Active	MSTN	2015	no	YES	no
domvanalimab	Whole mAb	Phase-III	Active	TIGIT	2020	no	no	no
donanemab	Whole mAb	Phase-II	Active	APP	2018	no	no	no
dostarlimab	Whole mAb	Preregistration	Active	PDCD1	2018	no	no	no
dovanvetmab	Feline Whole mAb	Unknown	Active	IL31 (Feline)	2019	no	no	no
drozitumab	Whole mAb	Phase-II	Discontinued	TNFRSF10B	2010	YES	no	no
duligotuzumab	Whole mAb	Phase-II	Discontinued	ERBB3	2012	no	no	YES
dupilumab	Whole mAb	Approved	Active	IL4R	2012	YES	no	no
durvalumab	Whole mAb	Approved	Active	CD274	2014	YES	no	no
dusigitumab	Whole mAb	Phase-II	Discontinued	IGF1&IGF2	2012	no	no	no
duvortuxizumab	Bispecific scFv with Crossover	Phase-I	Discontinued	CD19;CD3E	2016	no;no	no;no	no;no
ebdarokimab	Whole mAb	Phase-I/II	Active	IL12B	2020	no	no	no
ebronucimab	Whole mAb	Phase-II	Active	PCSK9	2020	no	no	no
eculizumab	Whole mAb	Approved	Active	C5	2002	YES	no	no
edrecolomab	Whole mAb	Approved (w)	Discontinued	EPCAM	1995	no	no	no
efalizumab	Whole mAb	Approved	NFD	ITGAL	2001	YES	no	no
efungumab	scFv	Phase-III	Discontinued	Heat Shock Protein 90 Homolog	2006	no	no	no
eldelumab	Whole mAb	Phase-II	Discontinued	CXCL10	2013	no	no	no
elezanumab	Whole mAb	Phase-II	Active	RGMA	2016	no	no	no
elgemtumab	Whole mAb	Phase-I/II	Discontinued	ERBB3	2014	no	no	YES
elipovimab	Whole mAb	Phase-I	Active	HIV-1 gp120	2018	no	no	YES
elotuzumab	Whole mAb	Approved	NFD	SLAMF7	2008	no	no	no
eluvixtamab	Bispecific scFv	Phase-I	Active	CD33;CD3E	2020	no;no	no;no	no;no
emactuzumab	Whole mAb	Phase-II	Active	CSF1R	2014	YES	no	no
emapalumab	Whole mAb	Approved	NFD	IFNG	2016	no	no	no
emerfetamab	Bispecific scFv	Phase-I	Active	CD33;CD3E	2020	no;no	no;no	no;no
emibetuzumab	Whole mAb	Phase-II	Active	MET	2014	no	no	no
emicizumab	Bispecific mAb	Approved	NFD	F9;F10	2015	no;no	no;no	no;no
enapotamab	Whole mAb ADC	Phase-II	Discontinued	AXL	2017	no	no	no
enavatuzumab	Whole mAb	Phase-I	Discontinued	TNFRSF12A	2010	no	no	no
encelimab	Whole mAb	Phase-I	Active	LAG3	2019	no	no	no
enfortumab	Whole mAb ADC	Approved	NFD	PVRL4	2013	no	no	no
enibarcimab	Whole mAb	Phase-II	Active	ADM	2020	no	no	no
enoblituzumab	Whole mAb	Phase-II	Active	CD276	2015	no	no	no
enokizumab	Whole mAb	Phase-II	Discontinued	IL9	2010	no	no	no
enoticumab	Whole mAb	Phase-I	Discontinued	DLL4	2012	no	no	no
ensituximab	Whole mAb	Phase-II	Active	MUC5AC	2010	no	no	no
envafolimab	Single Domain Variable Fragment;H	Preregistration	Active	PDL1	2018	no	no	no
epcoritamab	Bispecific mAb	Phase-III	Active	CD3E;MS4A1	2019	no;no	no;no	no;YES
epratuzumab	Whole mAb	Phase-III	Discontinued	CD22	1999	no	YES	no
eptinezumab	Whole mAb	Approved	Active	CALCA&CALCB	2016	no	no	no
eramkafusp	Whole mAb Fusion	Phase-I	Active	CD20	2020	no	YES	no
erenumab	Whole mAb	Approved	NFD	CALCRL	2016	YES	no	no
erfonrilimab	Bispecific Single Domains (VH-VH'-CH)	Phase-II	Active	CD274;CTLA4	2020	no;YES	no;no	no;no
etaracizumab	Whole mAb	Phase-II	Discontinued	ITGAV_ITGB3	2008	no	no	no
etesevimab	Whole mAb	Approved	NFD	SARS-CoV-2 Spike RBD	2020	YES	no	no
etevritamab	Bispecific scFv	Phase-I	Discontinued	EGFR;CD3E	2020	no;no	no;no	no;no
etigilimab	Whole mAb	Phase-I/II	Active	TIGIT	2017	no	no	no
etokimab	Whole mAb	Phase-II	Discontinued	IL13	2018	no	no	no
etrolizumab	Whole mAb	Phase-III	Active	ITGA4_ITGB7&ITGAE_ITGB7	2010	no	no	no
evinacumab	Whole mAb	Approved	Active	ANGPTL3	2014	no	no	no
evolocumab	Whole mAb	Approved	Active	PCSK9	2012	no	no	no
ezabenlimab	Whole mAb	Phase-II	Active	PDCD1	2019	no	no	no
faricimab	Bispecific mAb	Phase-III	Active	VEGFA;ANGPT2	2017	YES;no	no;no	YES;YES
farletuzumab	Whole mAb	Phase-III	Active	FOLR1	2008	no	no	no
fasinumab	Whole mAb	Phase-III	Active	NGFB	2012	no	no	no
feladilimab	Whole mAb	Phase-III	Active	ICOS	2019	no	no	no
felzartamab	Whole mAb	Phase-III	Active	CD38	2019	no	no	no
fezakinumab	Whole mAb	Phase-I	Discontinued	IL22	2009	no	no	no
fianlimab	Whole mAb	Phase-I	Active	LAG3	2019	no	no	no
fibatuzumab	Whole mAb	Phase-II	Active	EPHA3	2015	no	no	no
ficlatuzumab	Whole mAb	Phase-II	Active	HGF	2011	no	no	no
figitumumab	Whole mAb	Phase-I	Discontinued	IGF1R	2008	no	no	no
finotonlimab	Whole mAb	Phase-III	Active	PDCD1	2020	no	no	no
firivumab	Whole mAb	Preclinical	Discontinued	Influenza A HA	2014	no	no	no
flanvotumab	Whole mAb	Phase-I	Discontinued	TYRP1	2011	no	no	no
fletikumab	Whole mAb	Phase-II	Discontinued	IL20	2013	no	no	no
flotetuzumab	Bispecific scFv with Crossover	Phase-I/II	Active	IL3RA;CD3E	2017	no;no	no;no	no;no
fontolizumab	Whole mAb	Phase-II	Discontinued	IFNG	2002	no	YES	no
foralumab	Whole mAb	Phase-I/II	Active	CD3E	2010	no	no	no
foravirumab	Whole mAb	Phase-II	Discontinued	RV Antigenic Site III	2008	no	no	no
fremanezumab	Whole mAb	Approved	Active	CALCA&CALCB	2016	no	no	no
fresolimumab	Whole mAb	Phase-I	Discontinued	TGFB	2009	no	YES	no
frovocimab	Whole mAb	Phase-II	Active	PCSK9	2018	no	no	no
frunevetmab	Feline Whole mAb	Unknown	Active	NGFB	2016	no	no	no
fulranumab	Whole mAb	Phase-III	Discontinued	NGFB	2010	no	YES	no
futuximab	Whole mAb	Phase-II	Active	EGFR	2012	no	no	no
galcanezumab	Whole mAb	Approved	NFD	CALCA&CALCB	2015	no	no	no
galiximab	Whole mAb	Phase-II	Discontinued	CD80	2003	no	no	no
gancotamab	scFv	Phase-II	Discontinued	ERBB2	2018	no	no	no
ganitumab	Whole mAb	Phase-III	Active	IGF1R	2010	no	no	no
gantenerumab	Whole mAb	Phase-III	Active	APP	2012	YES	no	no
garadacimab	Whole mAb	Phase-III	Active	F12	2018	no	no	no
garetosmab	Whole mAb	Phase-II	Active	INHBA	2018	no	no	no
garivulimab	Whole mAb	Phase-I/II	Active	CD274	2020	no	no	no
gatipotuzumab	Whole mAb	Phase-II	Active	MUC1	2016	no	no	no
gatralimab	Whole mAb	Phase-I	Discontinued	CD52	2019	YES	no	no
gedivumab	Whole mAb	Phase-II	Discontinued	Influenza A HA	2016	no	no	YES
gemtuzumab	Whole mAb ADC	Approved	NFD	CD33	2016	no	no	no
geptanolimab	Whole mAb	Preregistration	Active	PDCD1	2020	no	no	no
gevokizumab	Whole mAb	Phase-III	Active	IL1B	2010	YES	no	no
giloralimab	Whole mAb	Phase-I	Active	CD40	2019	no	no	no
gilvetmab	Canine Whole mAb	Unknown	Active	PDCD1 (Canine)	2016	no	no	no
gimsilumab	Whole mAb	Phase-I	Discontinued	CSF2	2017	no	no	no
girentuximab	Whole mAb Radiolabelled	Phase-III	Discontinued	CA9	2009	no	no	no
glembatumumab	Whole mAb ADC	Phase-III	Discontinued	GPNMB	2015	no	no	no
glenzocimab	Fab	Phase-II	Active	GP6	2018	no	no	no
glofitamab	Bispecific mAb with Domain Crossover	Phase-III	Active	CD3E;MS4A1	2019	no;YES	no;YES	no;YES
golimumab	Whole mAb	Approved	Active	TNFA	2004	YES	no	no
gomiliximab	Whole mAb	Phase-II	Discontinued	FCER2	2004	no	YES	no
gontivimab	Bispecific Single Domains (VH-VH'-VH’)	Phase-II	Discontinued	RSV gpF	2019	no;no	no;no	no;no
gosuranemab	Whole mAb	Phase-II	Active	MAPT	2018	no	no	no
gremubamab	Bispecific mAb	Phase-II	Discontinued	PcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas)	2019	no;no	no;no	no;no
grisnilimab	Whole mAb	Phase-I/II	Active	CD7	2020	no	no	no
guselkumab	Whole mAb	Approved	Active	IL23A	2013	YES	no	no
ianalumab	Whole mAb	Phase-II/III	Active	TNFRSF13C	2017	no	no	no
ibalizumab	Whole mAb	Approved	NFD	CD4	2007	YES	no	no
icatolimab	Whole mAb	Phase-I	Active	BTLA	2019	no	no	no
icrucumab	Whole mAb	Phase-II	Active	FLT1	2010	no	no	no
idactamab	Whole mAb	Phase-I	Active	SLC1A5	2020	no	no	no
idarucizumab	Fab	Approved	NFD	Dabigatran	2013	YES	no	no
ieramilimab	Whole mAb	Phase-II	Active	CD223	2018	no	no	no
ifabotuzumab	Whole mAb	Phase-II	Active	EPHA3	2015	no	no	no
iladatuzumab	Whole mAb ADC	Phase-I	Discontinued	CD79B	2017	no	no	no
imalumab	Whole mAb	Phase-II	Active	MIF	2014	YES	no	no
imaprelimab	Whole mAb	Phase-I	Discontinued	MCAM	2017	no	no	no
imdevimab	Whole mAb	Approved	Active	SARS-CoV-2 Spike RBD	2020	YES	no	no
imgatuzumab	Whole mAb	Phase-II	Discontinued	EGFR	2012	no	no	no
imsidolimab	Whole mAb	Phase-II	Active	IL36R	2020	no	no	no
inclacumab	Whole mAb	Phase-II	Discontinued	SELP	2011	no	no	no
indatuximab	Whole mAb ADC	Phase-II	Active	SDC1	2011	no	no	no
indusatumab	Whole mAb ADC	Phase-II	Discontinued	GUCY2C	2014	no	no	no
inebilizumab	Whole mAb	Approved	Active	CD19	2015	no	no	no
infliximab	Whole mAb	Approved	NFD	TNFA	1997	YES	no	no
inotuzumab	Whole mAb ADC	Approved	Active	CD22	2004	no	no	no
intetumumab	Whole mAb	Phase-II	Discontinued	ITGAV_ITGB3	2009	no	no	no
ipilimumab	Whole mAb	Approved	Active	CTLA4	2005	YES	no	no
iratumumab	Whole mAb	Phase-II	Discontinued	TNFRSF8	2005	no	no	no
isatuximab	Whole mAb	Approved	Active	CD38	2014	YES	no	no
iscalimab	Whole mAb	Phase-II	Active	CD40	2017	no	no	no
isecarosmab	Bispecific Single Domains (VH-VH')	Phase-I	Active	ADAMTSL5;ALB	2019	no;no	no;no	no;no
istiratumab	Bispecific Mixed mAb and scFv	Phase-II	Discontinued	IGF1R;ERBB3	2017	no;no	no;no	no;no
itepekimab	Whole mAb	Phase-III	Active	IL33	2019	no	no	no
itolizumab	Whole mAb	Approved	Active	CD6	2010	no	no	no
ivuxolimab	Whole mAb	Phase-II	Active	TNFRSF4	2019	no	no	no
ixekizumab	Whole mAb	Approved	Active	IL17A	2011	YES	YES	no
izuralimab	Bispecific Mixed mAb and scFv	Phase-I	Active	ICOS;PDCD1	2020	no;no	no;no	no;no
labetuzumab	Whole mAb ADC	Phase-II	Discontinued	CEACAM5	2015	no	no	no
lacnotuzumab	Whole mAb	Phase-II	Active	CSF1	2016	no	no	no
lacutamab	Whole mAb	Phase-II	Active	KIR3DL2	2018	no	no	no
ladiratuzumab	Whole mAb ADC	Phase-II	Active	SLC39A6	2017	no	no	no
lambrolizumab	Whole mAb	Approved	Active	PDCD1	2013	YES	no	no
lampalizumab	Fab	Phase-III	Discontinued	CFD	2012	YES	no	no
lanadelumab	Whole mAb	Approved	NFD	KLKB1	2015	YES	no	no
landogrozumab	Whole mAb	Phase-II	Active	MSTN	2015	no	no	no
laprituximab	Whole mAb ADC	Phase-I	Discontinued	EGFR	2015	no	no	no
larcaviximab	Whole mAb	Phase-II	Active	Zaire Ebolavirus GP	2016	no	YES	no
latozinemab	Whole mAb	Phase-III	Active	SORT1	2020	no	no	no
lebrikizumab	Whole mAb	Phase-III	Active	IL13	2009	YES	no	no
lecanemab	Whole mAb	Phase-III	Active	APP	2019	no	no	no
lemzoparlimab	Whole mAb	Phase-I/II	Active	CD47	2020	no	no	no
lenvervimab	Whole mAb	Phase-III	Active	HBV	2017	no	no	no
lenzilumab	Whole mAb	Phase-III	Active	CSF2	2014	no	no	no
leronlimab	Whole mAb	Phase-III	Active	CCR5	2017	no	no	no
lesofavumab	Whole mAb	Phase-I	Discontinued	Influenza B Virus	2016	no	no	no
letaplimab	Whole mAb	Phase-I/II	Active	CD47	2020	no	no	no
letolizumab	Single Domain Variable Fragment;H	Phase-I/II	Active	CD40LG	2016	no	no	no
levilimab	Whole mAb	Approved	Active	IL6R	2018	no	no	no
lexatumumab	Whole mAb	Phase-I	Discontinued	TNFRSF10B	2006	no	no	YES
licaminlimab	scFv	Phase-II	Active	TNFA	2020	no	no	no
lifastuzumab	Whole mAb ADC	Phase-II	Discontinued	SLC34A2	2013	no	no	no
ligelizumab	Whole mAb	Phase-III	Active	IGHE	2012	YES	no	no
lilotomab	Whole mAb ADC	Phase-II	Active	CD37	2014	no	no	no
lintuzumab	Whole mAb Radiolabelled	Phase-II	Discontinued	CD33	1996	no	no	no
lirentelimab	Whole mAb	Phase-III	Active	SIGLEC8	2020	no	no	no
lirilumab	Whole mAb	Phase-II	Active	KIRD2	2012	no	no	no
lodapolimab	Whole mAb	Phase-I	Active	PDL1	2019	no	no	no
lodelcizumab	Whole mAb	Phase-II	Discontinued	PCSK9	2012	no	no	no
lokivetmab	Canine Whole mAb	Approved	NFD	IL31	2014	no	no	no
loncastuximab	Whole mAb ADC	Preregistration	Active	CD19	2017	no	YES	no
lonigutamab	Whole mAb	Phase-I/II	Active	IGF1R	2020	no	no	no
lorukafusp	Whole mAb Fusion	Phase-II	Active	Ganglioside GD2	2018	no	no	YES
lorvotuzumab	Whole mAb ADC	Phase-II	Active	NCAM1	2010	no	no	no
losatuxizumab	Whole mAb ADC	Phase-I	Discontinued	EGFR	2016	no	no	no
lucatumumab	Whole mAb	Phase-I	Discontinued	CD40	2007	no	no	no
lulizumab	Single Domain Variable Fragment;L	Phase-II	Active	CD28	2014	no	no	no
lumiliximab	Whole mAb	Phase-II	Discontinued	FCER2	2004	no	YES	no
lumretuzumab	Whole mAb	Phase-I/II	Active	ERBB3	2014	YES	no	no
lupartumab	Whole mAb ADC	Phase-I	Active	LYPD3	2016	no	no	no
lusvertikimab	Whole mAb	Phase-I	Active	IL7R	2020	no	no	no
lutikizumab	Bispecific Dual Variable Domain IG	Phase-II	Discontinued	IL1A;IL1B	2016	no;no	no;no	no;no
maftivimab	Whole mAb	Preregistration	Discontinued	Zaire Ebolavirus GP	2018	no	no	no
magrolimab	Whole mAb	Phase-III	Active	CD47	2018	no	YES	no
manelimab	Whole mAb	Phase-I	Discontinued	PDL1	2019	no	no	no
margetuximab	Whole mAb	Approved	Active	ERBB2	2013	no	no	no
marstacimab	Whole mAb	Phase-III	Active	ERBB2	2013	no	no	no
matuzumab	Whole mAb	Phase-II	Discontinued	EGFR	2003	YES	YES	no
mavezelimab	Whole mAb	Phase-II	Active	LAG3	2019	no	no	no
mavrilimumab	Whole mAb	Phase-II/III	Active	CSF2RA	2009	no	no	no
melrilimab	Whole mAb	Phase-II	Discontinued	IL1RL1	2020	no	no	no
mepolizumab	Whole mAb	Approved	Active	IL5	1999	no	no	no
mezagitamab	Whole mAb	Phase-II	Active	CD38	2019	no	no	no
mibavademab	Whole mAb	Phase-II	Active	LEPR	2020	no	no	no
milatuzumab	Whole mAb	Phase-I/II	Discontinued	CD74	2007	no	no	no
mipasetamab	Whole mAb	Phase-I	Active	AXL	2020	no	no	no
miptenalimab	Whole mAb	Phase-II	Active	LAG3	2019	no	no	no
mirikizumab	Whole mAb	Phase-III	Active	IL23A	2017	no	no	no
miromavimab	Whole mAb (Mouse)	Approved	NFD	Rabies Virus Strain ERA GP Ectodomain Epitope G-II	2019	no	no	no
mirvetuximab	Whole mAb ADC	Phase-III	Active	FOLR1	2015	no	no	no
mirzotamab	Whole mAb	Phase-I	Active	CD276	2019	no	no	no
mitazalimab	Whole mAb	Phase-I	Active	CD40	2017	no	no	no
modakafusp	Whole mAb Fusion	Phase-I/II	Active	ADPRC	2019	no	no	no
modotuximab	Whole mAb	Phase-II	Active	EGFR	2012	no	no	no
mogamulizumab	Whole mAb	Approved	Active	CCR4	2010	no	no	no
monalizumab	Whole mAb	Phase-III	Active	KLRC1	2015	no	no	no
mosunetuzumab	Bispecific mAb	Phase-III	Active	CD3E;MS4A1	2017	no;no	no;no	no;YES
motavizumab	Whole mAb	Phase-III	Discontinued	RSV gpF	2006	YES	YES	no
moxetumomab	Fv Fusion	Approved	NFD	CD22	2009	no	no	no
murlentamab	Whole mAb	Phase-II	Active	AMHR2	2018	no	no	no
muromonab	Whole mAb	Approved	Discontinued	CD3E	1988	YES	no	no
nadecnemab	Whole mAb	Phase-II	Active	GFRA3	2020	no	no	no
namilumab	Whole mAb	Phase-II	Active	CSF2	2010	no	no	no
naptumomab	Fab Fusion	Phase-III	Discontinued	TPBG	2006	no	no	no
naratuximab	Whole mAb ADC	Phase-II	Active	CD37	2015	no	no	no
narnatumab	Whole mAb	Phase-I	Discontinued	MST1R	2011	no	no	no
narsoplimab	Whole mAb	Preregistration	Active	MASP2	2019	no	no	no
natalizumab	Whole mAb	Approved	Active	ITGA4	1998	no	YES	no
navicixizumab	Bispecific mAb	Phase-I	Active	DLL4;VEGFA	2015	no;no	no;no	no;no
navivumab	Whole mAb	Preclinical	Discontinued	Influenza A HA	2015	YES	YES	no
naxitamab	Whole mAb	Approved	Active	Ganglioside GD2	2018	no	no	no
necitumumab	Whole mAb	Approved	Active	EGFR	2008	YES	no	no
nemolizumab	Whole mAb	Phase-III	Active	IL31RA	2014	no	no	no
nesvacumab	Whole mAb	Phase-I	Discontinued	ANGPT2	2012	no	no	no
netakimab	Whole mAb	Approved	Active	IL17A	2017	no	no	no
nidanilimab	Whole mAb	Phase-II	Active	IL1RAP	2018	no	no	no
nimacimab	Whole mAb	Phase-II	Active	CNR1	2018	no	no	no
nimotuzumab	Whole mAb	Approved	Active	EGFR	2005	no	YES	no
nipocalimab	Whole mAb	Phase-III	Active	FCGRT	2019	no	no	YES
nirsevimab	Whole mAb	Phase-III	Active	RSV	2018	YES	no	YES
nivatrotamab	Bispecific Mixed mAb and scFv	Phase-I/II	Active	GD2;CD3E	2020	no;no	no;no	no;no
nivolumab	Whole mAb	Approved	Active	PDCD1	2012	YES	no	no
nurulimab	Whole mAb	Phase-I	Discontinued	CTLA4	2019	no	YES	no
obexelimab	Whole mAb	Phase-III	Active	CD19	2018	no	no	no
obiltoxaximab	Whole mAb	Approved	NFD	Anthrax Protective Antigen	2015	no	no	no
obinutuzumab	Whole mAb	Approved	Active	MS4A1	2008	YES	YES	no
obrindatamab	Bispecific scFv with Domain Crossover	Phase-I	Discontinued	CD276;CD3E	2020	no;no	no;no	no;no
ocaratuzumab	Whole mAb	Phase-II	Discontinued	MS4A1	2012	no	no	no
ociperlimab	Whole mAb	Phase-II	Active	TIGIT	2020	no	no	no
ocrelizumab	Whole mAb	Approved	NFD	MS4A1	2005	no	no	YES
odesivimab	Whole mAb	Approved	Active	Zaire Ebolavirus GP	2019	no	no	no
odronextamab	Bispecific mAb	Phase-II	Active	MS4A1;CD3E	2019	no;no	no;no	no;no
ofatumumab	Whole mAb	Approved	Active	MS4A1	2005	YES	no	no
olaratumab	Whole mAb	Approved	Active	PDGFRA	2010	no	no	no
oleclumab	Whole mAb	Phase-II	Active	NT5E	2016	no	no	no
olendalizumab	Whole mAb	Phase-II	Active	C5	2015	no	no	no
olinvacimab	Whole mAb	Phase-II	Active	KDR	2018	no	no	no
olokizumab	Whole mAb	Phase-III	Active	IL6	2010	YES	no	no
omalizumab	Whole mAb	Approved	Active	IGHE	2000	YES	YES	no
omburtamab	Whole mAb Radiolabelled	Phase-II/III	Active	CD276	2018	YES	no	no
omodenbamab	Whole mAb	Phase-I/II	Active	SpA	2020	no	no	no
onartuzumab	Fab + di-Fc	Phase-III	Discontinued	MET	2010	YES	no	no
onfekafusp	Whole mAb Fusion	Phase-III	Active	FN extra domain B	2010	no	no	no
ongericimab	Whole mAb	Phase-II	Active	PCSK9	2019	no	no	no
ontamalimab	Whole mAb	Phase-III	Discontinued	MADCAM1	2018	YES	no	no
ontuxizumab	Whole mAb	Phase-II	Active	CD248	2013	no	no	no
onvatilimab	Whole mAb	Phase-I	Active	VSIR	2017	no	no	no
opicinumab	Whole mAb	Phase-II	Discontinued	LINGO1	2015	YES	no	no
oportuzumab	scFv	Preregistration	Active	EPCAM	2008	no	no	no
opucolimab	Whole mAb	Phase-I	Active	PDL1	2019	no	no	no
ordesekimab	Whole mAb	Phase-I/II	Active	IL15	2020	no	no	no
orilanolimab	Whole mAb	Phase-II	Active	FCGRT	2018	YES	no	no
orticumab	Whole mAb	Phase-II	Active	OxLDL	2012	no	no	no
osocimab	Whole mAb	Phase-II	Active	F11	2018	no	YES	no
otelixizumab	Whole mAb	Phase-II	Active	CD3E	2007	no	no	no
otilimab	Whole mAb	Phase-III	Active	CSF2	2018	no	YES	YES
otlertuzumab	di-scFv+Fc	Phase-II	Discontinued	CD37	2013	no	no	no
oxelumab	Whole mAb	Phase-II	Discontinued	TNFSF4	2010	no	no	no
ozanezumab	Whole mAb	Phase-II	Discontinued	RTN4	2012	no	no	no
ozoralizumab	Bispecific Single Domains (VH-VH'-VH)	Phase-III	Active	TNFA;ALB	2011	no;no	no;no	YES;no
pabinafusp	Whole mAb Fusion	Phase-III	Active	TFRC	2018	no	no	no
pacanalotamab	Bispecific scFv	Phase-I	Active	TNFRSF17;CD3E	2020	no;no	no;no	no;no
pacmilimab	Whole mAb	Phase-II	Active	PDL1	2019	no	no	no
palivizumab	Whole mAb	Approved	NFD	RSV gpF	1998	no	YES	no
pamrevlumab	Whole mAb	Phase-III	Active	CTGF	2015	no	no	no
panitumumab	Whole mAb	Approved	Active	EGFR	2004	YES	no	no
pankomab	Whole mAb	Phase-II	Active	MUC1	2016	no	no	no
panobacumab	Whole mAb	Phase-II	Active	Serotype IATS O11	2008	no	no	no
parsatuzumab	Whole mAb	Phase-II	Discontinued	EGFL7	2012	no	no	no
pasotuxizumab	Bispecific scFv	Phase-I	Discontinued	FOLH1;CD3E	2014	no;no	no;no	no;no
pateclizumab	Whole mAb	Phase-II	Discontinued	LTA	2011	YES	no	no
patritumab	Whole mAb	Phase-III	Active	ERBB3	2011	no	no	no
pavunalimab	Bispecific Mixed mAb and scFv	Phase-I	Active	LAG3;CTLA4	2020	no;no	no;no	no;no
pavurutamab	Bispecific scFv	Phase-I	Active	TNFRSF17;CD3E	2020	no;no	no;no	no;no
pelgifatamab	Whole mAb ADC	Phase-I	Active	FOLH1	2020	no	no	no
pembrolizumab	Whole mAb	Approved	Active	PDCD1	2013	YES	no	no
penpulimab	Whole mAb	Phase-III	Active	PDCD1	2020	no	no	no
pepinemab	Whole mAb	Phase-II	Active	SEMA4D	2018	no	no	no
perakizumab	Whole mAb	Phase-I	Discontinued	IL17A	2012	no	no	no
pertuzumab	Whole mAb	Approved	Active	ERBB2	2003	YES	no	YES
petosemtamab	Bispecific mAb	Phase-I	Active	EGFR;LGR5	2019	no;no	no;no	no;no
pidilizumab	Whole mAb	Phase-II	Active	PDCD1	2012	no	no	no
pimivalimab	Whole mAb	Phase-II	Active	PDCD1	2020	no	no	no
pimurutamab	Whole mAb	Phase-I/II	Active	EGFR	2019	no	no	no
pinatuzumab	Whole mAb ADC	Phase-II	Discontinued	CD22	2012	no	YES	no
placulumab	Single Domain Variable Fragment (VL) + Fc	Phase-II	Discontinued	TNFA	2012	no	no	no
plamotamab	Bispecific Mixed mAb and scFv	Phase-I	Active	MS4A1;CD3E	2018	no;no	no;no	no;no
plonmarlimab	Whole mAb	Phase-II/III	Active	CSF2	2020	no	no	no
plozalizumab	Whole mAb	Phase-II	Active	CCR2	2015	no	no	no
pogalizumab	Whole mAb	Phase-II	Discontinued	TNFRSF4	2015	YES	no	no
polatuzumab	Whole mAb ADC	Approved	Active	CD79B	2012	no	no	no
ponezumab	Whole mAb	Phase-II	Discontinued	APP	2010	YES	no	no
ponsegromab	Whole mAb	Phase-I	Active	GDF15	2020	no	no	no
porgaviximab	Whole mAb	Phase-II	Active	Zaire Ebolavirus GP	2016	no	YES	no
praluzatamab	Whole mAb	Phase-II	Active	CD166	2019	no	no	no
prasinezumab	Whole mAb	Phase-II	Active	SNCA	2017	no	no	no
prezalumab	Whole mAb	Phase-II	Discontinued	ICOSLG	2015	YES	no	no
pritoxaximab	Whole mAb	Phase-II	Discontinued	Shiga Toxin Type 1	2012	no	no	no
prolgolimab	Whole mAb	Phase-III	Active	PDCD1	2018	no	no	no
pucotenlimab	Whole mAb	Phase-II	Active	PDCD1	2020	no	no	no
quavonlimab	Whole mAb	Phase-II	Active	CTLA4	2019	no	no	no
quetmolimab	Whole mAb	Phase-II	Active	CX3CL1	2018	no	no	no
quilizumab	Whole mAb	Phase-II	Discontinued	IGHE	2011	YES	no	no
racotumomab	Whole mAb	Approved	Active	Idiotope of anti-NeuGc-ganliosides	2008	no	no	no
radretumab	di-scFv + CH4	Phase-II	Discontinued	FN extra domain B	2010	no	no	no
rafivirumab	Whole mAb	Phase-II	Discontinued	RV Antigenic Site III	2008	no	no	no
ragifilimab	Whole mAb	Phase-II	Active	TNFRSF18	2019	no	no	no
ralpancizumab	Whole mAb	Phase-I	Discontinued	PCSK9	2013	no	no	YES
ramucirumab	Whole mAb	Approved	Active	KDR	2008	YES	no	no
ranevetmab	Canine Whole mAb	Unknown	Active	NGFB	2016	no	no	no
ranibizumab	Fab	Approved	Active	VEGFA	2004	YES	no	YES
ravagalimab	Whole mAb	Phase-II	Active	CD40	2017	YES	no	no
ravulizumab	Whole mAb	Approved	Active	C5	2017	no	YES	no
recaticimab	Whole mAb	Phase-I	Active	PCSK9	2020	no	no	no
refanezumab	Whole mAb	Phase-II	Discontinued	MAG	2015	no	no	no
regdanvimab	Whole mAb	Approved	Active	SARS-CoV-2 Spike RBD	2020	YES	no	no
relatlimab	Whole mAb	Phase-II/III	Active	LAG3	2018	no	no	no
relfovetmab	Feline Whole mAb	Unknown	Active	NGFB	2018	no	no	no
remtolumab	Bispecific Dual Variable Domain IG	Phase-II	Discontinued	IL17A;TNFA	2016	YES;YES	YES;no	no;no
reslizumab	Whole mAb	Approved	Active	IL5	2001	no	no	no
retifanlimab	Whole mAb	Preregistration	Active	PDCD1	2019	no	no	no
retlirafusp	Whole mAb Fusion	Phase-I/II	Active	CD274	2020	no	no	no
revdofilimab	Whole mAb	Phase-I	Active	TNFRSF4	2019	no	no	no
rilotumumab	Whole mAb	Phase-II	Discontinued	HGF	2009	no	no	no
rinucumab	Whole mAb	Phase-II	Discontinued	PDGFRB	2015	no	no	no
ripertamab	Whole mAb	Phase-III	Active	MS4A1	2019	YES	YES	no
risankizumab	Whole mAb	Approved	Active	IL23A	2015	no	no	no
rituximab	Whole mAb	Approved	Active	MS4A1	1997	YES	YES	no
rivabazumab	Fab	Phase-II	Discontinued	PcrV type III secretion system	2015	no	no	no
robatumumab	Whole mAb	Phase-II	Discontinued	IGF1R	2008	no	no	no
roledumab	Whole mAb	Phase-II/III	Active	RHD	2010	no	no	no
rolinsatamab	Whole mAb ADC	Phase-I	Active	PRLR	2018	no	no	no
romilkimab	Bispecific Dual Variable Domain IG	Phase-II	Active	IL13;IL4	2017	no;no	no;no	no;no
romosozumab	Whole mAb	Approved	NFD	SOST	2011	no	no	no
rontalizumab	Whole mAb	Phase-II	Discontinued	IFNA1	2009	YES	no	no
rosmantuzumab	Whole mAb	Phase-I	Discontinued	RSPO3	2016	no	no	no
rosopatamab	Whole mAb	Phase-II	Active	FOLH1	2019	no	no	no
rovalpituzumab	Whole mAb ADC	Phase-III	Discontinued	DLL3	2015	no	no	no
rozanolixizumab	Whole mAb	Phase-III	Active	FCGRT	2016	YES	no	no
rozibafusp	Whole mAb Fusion	Phase-II	Active	ICOS	2018	YES	no	no
runimotamab	Bispecific mAb	Phase-I	Active	ERBB2;CD3E	2020	YES;no	YES;no	YES;no
ruplizumab	Whole mAb	Phase-II	Discontinued	CD40LG	2000	YES	no	no
sabatolimab	Whole mAb	Phase-III	Active	HAVCR2	2019	no	no	no
sacituzumab	Whole mAb ADC	Approved	Active	TACSTD2	2016	no	no	no
samalizumab	Whole mAb	Phase-I	Discontinued	CD200	2010	no	no	no
samrotamab	Whole mAb ADC	Phase-I	Active	LRRC15	2017	no	no	no
sapelizumab	Whole mAb	Approved	NFD	IL6R	2015	no	no	no
sarilumab	Whole mAb	Approved	Active	IL6R	2011	no	no	no
sasanlimab	Whole mAb	Phase-III	Active	PDCD1	2019	YES	no	no
satralizumab	Whole mAb	Approved	NFD	IL6R	2015	no	no	no
secukinumab	Whole mAb	Approved	Active	IL17A	2009	YES	no	no
selicrelumab	Whole mAb	Phase-I	Active	CD40	2016	no	no	no
semorinemab	Whole mAb	Phase-II	Active	MAPT	2018	no	no	no
serclutamab	Whole mAb ADC	Phase-I	Discontinued	EGFR	2016	no	no	no
seribantumab	Whole mAb	Phase-II	Discontinued	ERBB3	2012	no	no	no
serplulimab	Whole mAb	Phase-III	Active	PDCD1	2019	no	no	no
setoxaximab	Whole mAb	Phase-II	Discontinued	Shiga Toxin Type 2	2012	no	no	no
setrusumab	Whole mAb	Phase-II	Active	SOST	2017	no	no	no
sibeprenlimab	Whole mAb	Phase-I	Active	TNFSF13	2020	no	no	no
sifalimumab	Whole mAb	Phase-II	Discontinued	IFNA1	2009	YES	no	no
siltuximab	Whole mAb	Approved	Active	IL6	2008	no	no	no
simlukafusp	Whole mAb Fusion	Phase-I	Active	FAP	2019	no	no	no
simtuzumab	Whole mAb	Phase-II	Discontinued	LOXL2	2012	no	no	no
sintilimab	Whole mAb	Approved	Active	PDCD1	2018	no	no	no
sirtratumab	Whole mAb ADC	Phase-I	Active	SLITRK6	2017	no	no	no
sirukumab	Whole mAb	Phase-III	Active	IL6	2011	no	no	no
sofituzumab	Whole mAb ADC	Phase-I	Discontinued	MUC16	2013	no	no	no
solanezumab	Whole mAb	Phase-III	Active	APP	2008	no	YES	no
solitomab	Bispecific scFv	Phase-I	Discontinued	EPCAM;CD3E	2011	no;no	no;no	no;no
sotigalimab	Whole mAb	Phase-II	Active	CD40	2020	no	no	no
sotrovimab	Whole mAb	Preregistration	Active	SARS-CoV-2 Spike RBD	2020	no	YES	no
spartalizumab	Whole mAb	Phase-II	Active	PDCD1	2017	no	no	no
spesolimab	Whole mAb	Phase-III	Active	IL36RN	2018	YES	no	no
sudubrilimab	Whole mAb	Unknown	Active	CD274	2020	no	no	YES
sugemalimab	Whole mAb	Phase-III	Preregistration	PDL1	2019	no	no	no
suptavumab	Whole mAb	Phase-III	Discontinued	RSV gpF	2016	no	no	no
surzebiclimab	Whole mAb	Phase-I/II	Active	HAVCR2	2020	no	no	no
sutimlimab	Whole mAb	Preregistration	Active	C1S	2017	no	no	no
suvizumab	Whole mAb	Phase-I	Discontinued	HIV-1 gp120	2009	YES	no	no
suvratoxumab	Whole mAb	Phase-II	Active	Toxin A	2016	YES	no	no
tabalumab	Whole mAb	Phase-III	Discontinued	TNFSF13B	2011	no	no	no
tabituximab	Whole mAb ADC	Phase-I	Discontinued	FZD10	2018	no	no	no
tadocizumab	Fab	Phase-II	Discontinued	ITGA2B_ITGB3	2005	no	no	no
tafasitamab	Whole mAb	Approved	Active	CD19	2018	no	no	no
tafolecimab	Whole mAb	Phase-III	Active	PCSK9	2019	no	no	no
talacotuzumab	Whole mAb	Phase-III	Active	IL3RA	2017	YES	no	no
talquetamab	Bispecific mAb	Phase-II	Active	GPRC5D;CD3E	2019	no;no	no;no	no;no
tamrintamab	Whole mAb ADC	Phase-I	Active	DPEP3	2018	YES	no	no
tamtuvetmab	Canine Whole mAb	Unknown	Active	CD52	2015	no	no	YES
tanezumab	Whole mAb	Preregistration	Active	NGFB	2008	YES	no	no
tanibirumab	Whole mAb	Phase-II	Active	KDR	2018	no	no	no
tarextumab	Whole mAb	Phase-II	Active	NOTCH2&3	2013	no	no	no
tarlatamab	Bispecific scFv	Phase-I	Active	DLL3;CD3E	2020	no;no	no;no	no;no
tavolimab	Whole mAb	Phase-II	Discontinued	TNFSF4	2016	no	no	no
tavolixizumab	Whole mAb	Phase-II	Discontinued	TNFSF4	2016	no	no	no
tebentafusp	scFv Fusion	Phase-III	Active	CD3E	2017	no	no	no
tebotelimab	Bispecific scFv with Crossover	Phase-II/III	Active	PDCD1;LAG3	2019	no;no	no;no	no;no
teclistamab	Bispecific mAb	Phase-II	Active	TNFRSF17;CD3E	2018	no;no	no;no	no;no
telazorlimab	Whole mAb	Phase-II	Active	TNFRSF4	2019	no	no	no
telisotuzumab	Whole mAb ADC	Phase-I	Discontinued	MET	2016	no	no	no
temelimab	Whole mAb	Phase-II	Active	MRSV envelope protein	2018	no	no	no
tenatumomab	Whole mAb Radiolabelled	Phase-I	Discontinued	TNC	2007	no	no	no
teplizumab	Whole mAb	Preregistration	Active	CD3E	2007	no	no	no
tepoditamab	Bispecific mAb	Phase-I	Active	CLEC12A;CD3E	2017	no;no	no;no	no;no
teprotumumab	Whole mAb	Approved	Active	IGF1R	2009	no	no	no
tesidolumab	Whole mAb	Phase-II	Active	C5	2014	no	no	no
tesnatilimab	Whole mAb	Phase-II	Active	KLRK1	2019	no	no	no
tezepelumab	Whole mAb	Phase-III	Active	TSLP	2015	YES	no	no
tibulizumab	Bispecific Mixed mAb and scFv	Phase-I	Discontinued	TNFSF13B;IL17A	2017	no;no	no;no	no;YES
ticilimumab	Whole mAb	Phase-III	Active	CTLA4	2005	YES	no	no
tidutamab	Bispecific Mixed mAb and scFv	Phase-I	Discontinued	SSTR2;CD3E	2018	no;no	no;no	no;no
tigatuzumab	Whole mAb	Phase-II	Discontinued	TNFRSF10B	2007	no	no	no
tilavonemab	Whole mAb	Phase-II	Active	MAPT	2018	no	no	no
tildrakizumab	Whole mAb	Approved	Active	IL23A	2012	no	no	no
tilogotamab	Whole mAb	Phase-I/II	Active	TNFRSF10B	2019	no	YES	no
tilvestamab	Whole mAb	Phase-I	Active	AXL	2019	no	no	no
timigutuzumab	Whole mAb	Phase-I	NFD	ERBB2	1997	YES	YES	YES
timolumab	Whole mAb	Phase-II	Discontinued	AOC3	2015	no	no	no
tinurilimab	Whole mAb	Phase-I	Active	CEACAM6	2019	no	no	no
tiragolumab	Whole mAb	Phase-III	Active	TIGIT	2017	no	no	no
tirnovetmab	Whole mAb (Canine)	Unknown	Active	IL31 (Canine)	2020	no	no	no
tislelizumab	Whole mAb	Approved	Active	PDCD1	2017	YES	no	no
tisotumab	Whole mAb	Preregistration	Active	F3	2015	no	no	no
tixagevimab	Whole mAb	Phase-III	Active	SARS-CoV-2 Spike RBD	2020	no	no	no
tocilizumab	Whole mAb	Approved	Active	IL6R	2004	no	no	no
tomaralimab	Whole mAb	Phase-II	Active	TLR2	2018	no	no	no
tomuzotuximab	Whole mAb	Phase-II	Active	EGFR	2016	no	YES	YES
toripalimab	Whole mAb	Approved	Active	PDCD1	2018	YES	no	no
torudokimab	Whole mAb	Phase-II	Active	IL33	2020	no	no	no
tosatoxumab	Whole mAb	Phase-III	Active	Toxin A	2013	no	no	no
tovetumab	Whole mAb	Phase-II	Discontinued	PDGFRA	2013	no	no	no
tozorakimab	Whole mAb	Phase-II	Active	IL33	2020	no	no	no
tralokinumab	Whole mAb	Preregistration	Active	IL13	2009	YES	no	no
trastuzumab	Whole mAb	Approved	NFD	ERBB2	1997	YES	YES	YES
tregalizumab	Whole mAb	Phase-II	Discontinued	CD4	2010	no	no	no
tremelimumab	Whole mAb	Phase-III	Active	CTLA4	2005	YES	no	no
trevogrumab	Whole mAb	Phase-II	Active	MSTN	2015	no	no	no
tusamitamab	Whole mAb	Phase-III	Active	CEACAM5	2020	no	no	no
ublituximab	Whole mAb	Preregistration	Active	MS4A1	2010	no	no	no
uliledlimab	Whole mAb	Phase-I/II	Active	NT5E	2020	no	no	no
ulocuplumab	Whole mAb	Phase-I/II	Active	CXCR4	2013	no	no	no
unasnemab	Whole mAb	Phase-I	Active	RGMA	2020	no	no	no
upifitamab	Whole mAb	Phase-I	Active	SLC34A2	2019	no	no	no
urabrelimab	Whole mAb	Phase-I	Active	CD47	2019	no	no	no
urelumab	Whole mAb	Phase-II	Active	TNFRSF9	2010	YES	no	no
ustekinumab	Whole mAb	Approved	Active	IL12B	2008	YES	no	no
utomilumab	Whole mAb	Phase-II	Active	TNFRSF9	2016	YES	no	no
vadastuximab	Whole mAb ADC	Phase-III	Discontinued	CD33	2015	no	no	no
valanafusp	Whole mAb Fusion	Phase-II	Active	INSR	2017	no	YES	YES
vanalimab	Whole mAb	Phase-I	Active	CD40	2017	no	no	no
vandortuzumab	Whole mAb ADC	Phase-I	Discontinued	STEAP1	2014	no	no	no
vantictumab	Whole mAb	Phase-I	Discontinued	FZD Family	2013	no	no	no
vanucizumab	Bispecific mAb	Phase-II	Discontinued	ANGPT2;VEGFA	2014	YES;YES	no;no	no;YES
varisacumab	Whole mAb	Phase-II/III	Active	VEGFA	2016	no	no	no
varlilumab	Whole mAb	Phase-II	Active	CD27	2014	no	no	no
vatelizumab	Whole mAb	Phase-II/III	Discontinued	ITGA2	2011	no	no	no
vedolizumab	Whole mAb	Approved	Active	ITGA4_ITGB7	2008	no	no	no
veltuzumab	Whole mAb	Phase-II	Discontinued	MS4A1	2007	no	no	no
vesencumab	Whole mAb	Phase-I	Discontinued	NRP1	2010	YES	no	no
vibecotamab	Bispecific Mixed mAb and scFv	Phase-I	Active	IL3RA;CD3E	2018	no;no	no;no	no;no
vibostolimab	Whole mAb	Phase-III	Active	TIGIT	2019	no	no	no
vilobelimab	Whole mAb	Phase-III	Active	C5	2019	no	no	no
visilizumab	Whole mAb	Phase-III	Discontinued	CD3E	2000	no	no	no
vixarelimab	Whole mAb	Phase-II	Active	OSMR	2020	no	no	no
vixtimotamab	Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)	Phase-I	Active	CD3E;CD33	2020	no;no	no;no	no;no
vobarilizumab	Bispecific Single Domains (VH-VH')	Phase-II	Active	IL6R;ALB	2015	no;no	no;no	no;no
vofatamab	Whole mAb	Phase-I/II	Active	FGFR3	2018	no	no	YES
volagidemab	Whole mAb	Phase-II	Active	GCCR	2018	no	YES	no
vonlerolizumab	Whole mAb	Phase-II	Discontinued	TNFRSF4	2015	YES	no	no
vopratelimab	Whole mAb	Phase-II	Active	ICOS	2017	no	no	no
vorsetuzumab	Whole mAb ADC	Phase-I	Discontinued	CD70	2012	no	no	no
vudalimab	Bispecific Mixed mAb and scFv	Phase-I	Active	CTLA4;PDCD1	2020	no;no	no;no	YES;no
vulinacimab	Whole mAb	Phase-I	Active	VEGFR2	2019	no	no	no
vunakizumab	Whole mAb	Phase-II	Active	IL17A	2016	no	no	no
xentuzumab	Whole mAb	Phase-II	Active	IGF1&IGF2	2015	no	no	no
zagotenemab	Whole mAb	Phase-II	Active	MAPT	2019	no	no	no
zalifrelimab	Whole mAb	Phase-II	Active	CTLA4	2018	no	no	no
zalutumumab	Whole mAb	Phase-II	Discontinued	EGFR	2005	no	no	no
zampilimab	Whole mAb	Phase-I/II	Active	TGM2	2018	no	no	no
zanidatamab	Bispecific mAb	Phase-II	Active	ERBB2;ERBB2	2019	no;YES	no;YES	YES;YES
zanolimumab	Whole mAb	Phase-III	Discontinued	CD4	2004	no	no	no
zansecimab	Whole mAb	Phase-II	Active	ANGPT2	2020	no	no	no
zatuximab	Whole mAb	Phase-II	Active	EGFR	2012	no	no	no
zelminemab	Whole mAb	Phase-II	Active	ADCYAP1R1	2019	no	no	no
zeluvalimab	Whole mAb	Phase-I	Active	PDCD1	2020	no	no	no
zenocutuzumab	Bispecific mAb	Phase-II	Active	ERBB3;ERBB2	2017	YES;YES	no;no	no;no
zilovertamab	Whle mAb	Phase-I/II	Active	ROR1	2020	no	no	no
ziltivekimab	Whole mAb	Phase-II	Active	IL6	2019	no	no	no
zimberelimab	Whole mAb	Preregistration	Active	PDCD1	2020	no	no	no
zolbetuximab	Whole mAb	Phase-III	Active	CLDN18	2017	no	no	no
zolimomab	Whole mAb	Approved	Discontinued	CD3E	1988	YES	no	no
zuberitamab	Whole mAb	Phase-II	Discontinued	MS4A1	2019	no	no	YES

Search again

> About

This database is described in the following paper: Raybould MIJ, Marks C, Lewis AP, Shi J, Bujotzek A, Taddese B, Deane CM (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):gkz827.

Antibody- and Nanobody-derived therapeutics with known sequences, and their structural coverage in the PDB.

Use the 'Get all therapeutics' tab to get a list of all immunotherapeutics.

Search by name: Find a specific entry using its INN -mab or -fusp name.

Search by attribute: Find a subset of immunotherapeutics with particular attributes. Choose from format, target, highest clinical trial reached, development status, year INN proposed, or structural coverage (or any combination).

Search by sequence: Find therapeutics near to your query sequence over any Chothia-defined region of the heavy and/or light chain variable domain sequence.

For more help, see the About page.

If you believe we have missed a WHO-recognised therapeutic with a public sequence, please contact us at opig <~at~> stats.ox.ac.uk

>   Get all immunotherapeutics

>   Search for a specific therapeutic

Please type a therapeutic INN name:

>   Search therapeutics by attribute

Therapeutic format:

Year INN Proposed:

Highest Clinical Trial:

Developmental Status:

Target:

Restrict to Known Structures:

>   Search for therapeutics by sequence similarity

Heavy chain sequence:

load example

Light chain sequence:

load example

Max No. of Therapeutics to be returned:

Minimum sequence identity:

Region to consider:

>   Downloads

Thera-SAbDab tracks all WHO-recognised Antibody- and Nanobody-derived therapeutics with released sequences.

Download a spreadsheet of all therapeutic sequences/structures (last list(s) - PL124+PL124-COVID): xlsx / csv

If you believe we have missed a WHO-recognised therapeutic with a public sequence, please contact us at opig <~at~> stats.ox.ac.uk

Thera-SAbDab

(Therapeutic Structural Antibody Database)

Search results

Search again